Billionaire Stanley Druckenmiller is pouring millions of dollars into two stocks after dumping two of the hottest equities on ...
A solid clinical win for a promising candidate helped jolt the stock a few months ago. And just last week, the company's ...
Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy. Learn why LLY ...
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...
The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...
Hims & Hers Health stock has seen its consensus analyst price target decrease from $47.42 to $46.67 per share. This shift comes as analysts weigh ongoing opportunities for growth against signals of ...
Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.
A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...
Stocktwits on MSN
Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data
Bank of America called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target.
Eli Lilly & Company (NYSE:LLY) continues to stand out as a significant player in the pharmaceutical sector, particularly recognized for its robust earnings growth projections over the next five years.
Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback